These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8698676)

  • 1. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.
    Ereshefsky L; Riesenman C; Lam YW
    J Clin Psychiatry; 1996; 57 Suppl 8():17-24; discussion 25. PubMed ID: 8698676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the risk of drug-drug interactions: a goal of rational drug development.
    Preskorn SH
    J Clin Psychiatry; 1996; 57 Suppl 1():3-6. PubMed ID: 8617709
    [No Abstract]   [Full Text] [Related]  

  • 4. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.
    Riesenman C
    Pharmacotherapy; 1995; 15(6 Pt 2):84S-99S. PubMed ID: 8587855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
    Schmider J; Greenblatt DJ; von Moltke LL; Karsov D; Shader RI
    Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer antidepressants and the cytochrome P450 system.
    Nemeroff CB; DeVane CL; Pollock BG
    Am J Psychiatry; 1996 Mar; 153(3):311-20. PubMed ID: 8610817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.
    Tremaine LM; Wilner KD; Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():31-6. PubMed ID: 9068933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
    McKillop D; Wild MJ; Butters CJ; Simcock C
    Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
    Hemeryck A; De Vriendt C; Belpaire FM
    Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
    Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
    Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.